Log in

Relevant bibliographies by topics / Antibodies / Journal articles

To see the other types of publications on this topic, follow the link: Antibodies.

Journal articles on the topic 'Antibodies'

Author: Grafiati

Published: 4 June 2021

Last updated: 29 July 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Antibodies.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Deora, Kanika, and Ruchee Khanna. "Clinical Profile of the Patients with Antiphospholipid Antibodies: Lupus Anticoagulant and Anticardiolipin Antibodies." Indian Journal of Forensic Medicine and Pathology 12, no. 3 (2019): 195–99. http://dx.doi.org/10.21088/ijfmp.0974.3383.12319.6.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Chiswell, David J., and John McCaffery. "Phage antibodies: will new ‘coliclonal’ antibodies replace monoclonal antibodies?" Trends in Biotechnology 10 (1992): 80–84. http://dx.doi.org/10.1016/0167-7799(92)90178-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

3

Linhardt, Robert J., C. W. Abell, R. M. Denney, B. W. Altrock, R. Auerbach, S. D. Bernal, R. E. Canfield, et al. "Monoclonal antibodies and immobilized antibodies." Applied Biochemistry and Biotechnology 15, no. 1 (June 1987): 53–80. http://dx.doi.org/10.1007/bf02798506.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Favoreel, Herman W., Geert Van Minnebruggen, Gerlinde R. Van de Walle, Jolanta Ficinska, and Hans J. Nauwynck. "Herpesvirus interference with virus-specific antibodies: Bridging antibodies, internalizing antibodies, and hiding from antibodies." Veterinary Microbiology 113, no. 3-4 (March 2006): 257–63. http://dx.doi.org/10.1016/j.vetmic.2005.11.003.

Full text

APA, Harvard, Vancouver, ISO, and other styles

5

Clark, A. "Antibodies." Journal of Clinical Pathology 42, no. 5 (May 1, 1989): 559. http://dx.doi.org/10.1136/jcp.42.5.559-c.

Full text

APA, Harvard, Vancouver, ISO, and other styles

6

Bradbury, Andrew, Nileena Velappan, Vittorio Verzillo, Milan Ovecka, Leslie Chasteen, Daniele Sblattero, Roberto Marzari, Jianlong Lou, Robert Siegel, and Peter Pavlik. "Antibodies in proteomics I: generating antibodies." Trends in Biotechnology 21, no. 6 (June 2003): 275–81. http://dx.doi.org/10.1016/s0167-7799(03)00112-4.

Full text

APA, Harvard, Vancouver, ISO, and other styles

7

Kounis, Nicholas G., George D. Soufras, and George N. Kounis. "Antibodies against antibodies inducing Kounis syndrome." International Journal of Cardiology 168, no. 5 (October 2013): 4804–5. http://dx.doi.org/10.1016/j.ijcard.2013.07.037.

Full text

APA, Harvard, Vancouver, ISO, and other styles

8

Trier, Nicole, Paul Hansen, and Gunnar Houen. "Peptides, Antibodies, Peptide Antibodies and More." International Journal of Molecular Sciences 20, no. 24 (December 13, 2019): 6289. http://dx.doi.org/10.3390/ijms20246289.

Full text

Abstract:

The applications of peptides and antibodies to multiple targets have emerged as powerful tools in research, diagnostics, vaccine development, and therapeutics. Antibodies are unique since they, in theory, can be directed to any desired target, which illustrates their versatile nature and broad spectrum of use as illustrated by numerous applications of peptide antibodies. In recent years, due to the inherent limitations such as size and physical properties of antibodies, it has been attempted to generate new molecular compounds with equally high specificity and affinity, albeit with relatively low success. Based on this, peptides, antibodies, and peptide antibodies have established their importance and remain crucial reagents in molecular biology.

APA, Harvard, Vancouver, ISO, and other styles

9

Matraszek, Veronika Viktoria, Hynek Heřman, and Ilona Hromadníková. "The relevance of antiphospholipid antibodies in obstetrics." Česká gynekologie 89, no. 3 (June 22, 2024): 237–44. http://dx.doi.org/10.48095/cccg2024237.

Full text

Abstract:

Summary: Aim and methodology: To provide a comprehensive review on new findings and current recommendations regarding antiphospholipid antibodies with particular emphasis on clinical impact on gestation. Conclusion: Antiphospholipid antibodies are an important risk factor for the development of a series of pregnancy-related complications. Early diagnosis and appropriate therapy can reduce the incidence of pregnancy loss and pregnancy-related complications. Key words: antiphospholipid antibodies – antiphospholipid syndrome – lupus anticoagulant – anticardiolipin antibodies – anti-ß2-glycoprotein I antibodies

APA, Harvard, Vancouver, ISO, and other styles

10

Shoenfeld, Yehuda. "The idiotypic network in autoimmunity: antibodies that bind antibodies that bind antibodies." Nature Medicine 10, no. 1 (January 2004): 17–18. http://dx.doi.org/10.1038/nm0104-17.

Full text

APA, Harvard, Vancouver, ISO, and other styles

11

Bobrovnik, S. A., M. O. Demchenko, and S. V. Komisarenko. "Effect of trifluoroethanol on antibodies binding properties." Ukrainian Biochemical Journal 95, no. 1 (April 26, 2023): 20–30. http://dx.doi.org/10.15407/ubj95.01.020.

Full text

Abstract:

The studies on the influence of organic co-solvents on the structure and function of antibodies are of key interest, especially in view of antibodies broad use as recognizing elements in different analytical systems. Here we studied the effect of co-solvent 2,2,2-trifluoroethanol (TFE) on the ability of anti-ovalbumin monoclonal antibodies to interact with its specific antigen. Antibody affinity to antigen and the rate constants of antibody binding to immobilized antigen were analyzed. Changes in antibody reactivity with incubation time which depended on TFE concentration and temperature were revealed. When treatment of antibodies with TFE was carried out at 0°C, we observed nonlinear, non-monotonous changes of antibody reactivity with initial fast decrease and substantial increase that may be related to the loss of antigen binding reactivity by some part of antibodies at the start but its restoration when the incubation proceeds. Keywords: 2;2;2-trifluoroethanol, antibody affinity, antigen-antibody interaction, monoclonal antibodies, ovalbumin

APA, Harvard, Vancouver, ISO, and other styles

12

Qian, J., Y. Xing, D. Yufang, X. Deng, J. Zhao, Q. Wang, Z. Tian, M. LI, and X. Zeng. "OP0216 THE CLINICAL AND PATHOLOGICAL ROLES OF AUTOANTIBODIES TARGETING BMP SIGNALING IN SYSTEMIC LUPUS ERYTHEMATOSUS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION." Annals of the Rheumatic Diseases 82, Suppl 1 (May 30, 2023): 141.1–142. http://dx.doi.org/10.1136/annrheumdis-2023-eular.3682.

Full text

Abstract:

BackgroundPulmonary arterial hypertension (PAH) is one of the most severe complications and the leading cause of death in patients with systemic lupus erythematosus (SLE). Pathogenic mechanisms leading to SLE-PAH are still not fully understood. In idiopathic PAH, the dysfunction of the bone morphogenetic protein (BMP) pathway was found to be involved in pulmonary artery remodeling [1]. In SLE-PAH, our previous study identified serum autoantibodies targeting BMP receptors (BMPR) as the potential biomarker, including anti-BMPR2, BMPR1A, and Activin Receptor-Like Kinase type 1 (ALK1) antibodies [2]. However, the clinical and pathological roles of the above autoantibodies targeting BMP signaling in SLE-PAH remain uncertain.ObjectivesTo investigate the clinical and pathological roles of autoantibodies targeting BMPR2, BMPR1A, and ALK1 in SLE-PAH.MethodsPatients of SLE-PAH confirmed by right heart catheterization were enrolled and serum levels of autoantibodies targeting BMPR2, BMPR1A, and ALK1 were measured by ELISA. Patients with SLE-PAH were subtyped by cluster analysis. Survival and treatment goal achievement were further compared between different clusters. The Id1 and phospho-SMAD1/5 (p-SMAD1/5) levels were examined in human pulmonary artery endothelial cells (hPAEC) under the induction of BMP9 combined with anti-BMPR2, anti-ALK1, and anti-BMPR1A neutralizing antibodies (5 μg/mL). The effect of anti-ALK1 antibodies on the extent of monolayer permeability and apoptosis of hPAEC was further examined.Results60 SLE-PAH patients were enrolled and cluster analysis revealed two distinct clusters according to the positivity of autoantibodies targeting BMP signaling and clinical manifestations. Cluster 1 was a “low-antibody and high-disease activity” cluster while cluster 2 was a “high-antibody and low-disease activity” cluster. Patients in cluster 1 showed a higher proportion of nephropathy (76.9%) and SLE activity, however a low positivity rate of autoantibodies targeting BMP signaling. Patients in cluster 2 were characterized by a higher rate of anti-BMPR2 antibodies (82.4%), anti-ALK antibodies (70.6%), and lower SLE activity. Prognostic analysis showed that the proportion of patients who reached the treatment target was relatively higher in cluster 2. Mechanism study showed that the p-SMAD1/5 level and the Id1expression were decreased, indicating the suppression of BMP signaling in the presence of anti-ALK1 antibodies. Functional studies showed that anti-ALK1 antibodies increased the monolayer permeability of hPAEC. The late-stage apoptosis of hPAECs was also induced by anti-ALK1 antibodies.Table 1.The clinical features of the patients in cluster 1 and cluster 2.Cluster 1 (N=26)Cluster 2 (N=34)PAnti-BMPR2 antibodies5(19.2)28(82.4)<0.001Anti-BMPR1A antibodies8(30.2)4(1.8)0.068Anti-ALK antibodies5(19.2)24(70.6)<0.001Arthritis12(46.2)25(73.5)0.031Nephropathy20(76.9)1(2.9)<0.001SLEDAI5.46±4.282.62±2.100.001WHO III/IV17(65.4)14(41.2)0.063Figure 1.(A). Kaplan-Meier analysis of the prognosis of cluster1 and cluster2. (B) The level of Id1 expression under the induction of anti-BMPR2, anti-ALK1, and anti-BMPR1A antibodies in the presence or absence of BMP9. The ID1 (C) and p-Smad 1/5/8 (D) measured by western blotting under the induction of anti-ALK antibodies, BMP9, or anti-ALK antibodies+ BMP9. The fluorescence of the receiver plate well solution (E) and the percentage of late-stage apoptotic cells (E) under the induction of anti-ALK neutralizing antibodies.ConclusionThe serum positivity of autoantibodies targeting BMP signaling has clinical potential in dividing SLE-PAH patients into two distinct clusters. The anti-ALK1 antibodies can downregulate BMP signaling and mediate great permeability and apoptosis in hPAECs, which may be involved in the pathogenesis of SLE-PAH.References[1]Dewachter L, et.al. Eur Respir J 34 (5):1100-1110.[2]Xing Y, et.al. FASEB J 35 (12):e22044.AcknowledgementsWe thank CSTAR co-authors as following for assistance with cases collections.Disclosure of InterestsNone Declared.

APA, Harvard, Vancouver, ISO, and other styles

13

Dahl, Mark V., and Alina G. Bridges. "Intravenous immune globulin: Fighting antibodies with antibodies." Journal of the American Academy of Dermatology 45, no. 5 (November 2001): 775–83. http://dx.doi.org/10.1067/mjd.2001.119085.

Full text

APA, Harvard, Vancouver, ISO, and other styles

14

SHITARA, Kenya. "Potelligent Antibodies as Next Generation Therapeutic Antibodies." YAKUGAKU ZASSHI 129, no. 1 (January 1, 2009): 3–9. http://dx.doi.org/10.1248/yakushi.129.3.

Full text

APA, Harvard, Vancouver, ISO, and other styles

15

Methe, H. "Antibodies Stop Secretion of Antibodies in Lupus." Science Translational Medicine 4, no. 141 (July 4, 2012): 141ec115. http://dx.doi.org/10.1126/scitranslmed.3004529.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Filatova, Elena A., Grigory B. Krapivinsky, Grigory N. Filatov, Alisa V. Lazareva, and Evgeny E. Fesenko. "Antiidiotypic antibodies against anti-cGMP polyclonal antibodies." Biochimica et Biophysica Acta (BBA) - Biomembranes 1064, no. 2 (May 1991): 293–96. http://dx.doi.org/10.1016/0005-2736(91)90314-x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Khan, Ramsha, Melissa Menard, Chao-Ching Jen, Xi Chen, Peter A. A. Norris, and Alan H. Lazarus. "Inhibition of platelet phagocytosis as an in vitro predictor for therapeutic potential of RBC antibodies in murine ITP." Blood 135, no. 26 (June 25, 2020): 2420–24. http://dx.doi.org/10.1182/blood.2019003646.

Full text

Abstract:

Abstract Polyclonal anti-D is a first-line therapy for immune thrombocytopenia (ITP). Monoclonal antibodies are desirable alternatives, but none have yet proven successful despite their ability to opsonize erythrocytes (or red blood cells, RBCs) and cause anemia. Here, we examined 12 murine erythrocyte–specific antibodies of different specificity and subtypes and found that 8 of these antibodies could induce anemia in antigen-positive mice. Of these 8 antibodies, only 5 ameliorated ITP. All antibodies were examined for their in vitro ability to support macrophage-mediated phagocytosis of erythrocytes. Antibodies which supported erythrocyte phagocytosis in vitro successfully ameliorated ITP in vivo. To examine the ability of each antibody to inhibit phagocytosis of platelets, the antibodies were used to sensitize erythrocytes in vitro and these were added to a platelet phagocytosis assay. Antibodies that inhibited platelet phagocytosis in vitro also all ameliorated ITP in vivo. We conclude that inducing anemia is not a sufficient condition for amelioration of ITP but that the antibody’s ability to prevent platelet phagocytosis in vitro predicted its ability to ameliorate ITP. We suggest that inhibition of in vitro platelet phagocytosis may prove to be a valuable tool for determining which erythrocyte antibodies would likely be candidates for clinical use in ITP.

APA, Harvard, Vancouver, ISO, and other styles

18

Reddy, Raghuram, Joel Mintz, Roei Golan, Fakiha Firdaus, Roxana Ponce, Derek Van Booven, Aysswarya Manoharan, Isabelle Issa, Bonnie B. Blomberg, and Himanshu Arora. "Antibody Diversity in Cancer: Translational Implications and Beyond." Vaccines 10, no. 8 (July 22, 2022): 1165. http://dx.doi.org/10.3390/vaccines10081165.

Full text

Abstract:

Patients with cancer tend to develop antibodies to autologous proteins. This phenomenon has been observed across multiple cancer types, including bladder, lung, colon, prostate, and melanoma. These antibodies potentially arise due to induced inflammation or an increase in self-antigens. Studies focusing on antibody diversity are particularly attractive for their diagnostic value considering antibodies are present at an early diseased stage, serum samples are relatively easy to obtain, and the prevalence of antibodies is high even when the target antigen is minimally expressed. Conversely, the surveillance of serum proteins in cancer patients is relatively challenging because they often show variability in expression and are less abundant. Moreover, an antibody’s presence is also useful as it suggests the relative immunogenicity of a given antigen. For these reasons, profiling antibodies’ responses is actively considered to detect the spread of antigens following immunotherapy. The current review focuses on expanding the knowledge of antibodies and their diversity, and the impact of antibody diversity on cancer regression and progression.

APA, Harvard, Vancouver, ISO, and other styles

19

Heng, Boon Chin, Wenjin Huang, Xiufang Zhong, Ping Yin, and Guo Qing Tong. "Roles of Antiphospholipid Antibodies, Antithyroid Antibodies and Antisperm Antibodies in Female Reproductive Health." Integrative Medicine International 2, no. 1-2 (July 16, 2015): 21–31. http://dx.doi.org/10.1159/000381900.

Full text

APA, Harvard, Vancouver, ISO, and other styles

20

BYGREN, P., N. RASMUSSEN, B. ISAKSSON, and J. WIESLANDER. "Anti-neutrophil cytoplasm antibodies, anti-GBM antibodies and anti-dsDNA antibodies in glomerulonephritis." European Journal of Clinical Investigation 22, no. 12 (December 1992): 783–92. http://dx.doi.org/10.1111/j.1365-2362.1992.tb01447.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Kapustianenko, L. G. "POLYCLONAL ANTIBODIES AGAINST HUMAN PLASMINOGEN KRINGLE 5." Biotechnologia Acta 10, no. 3 (June 2017): 41–49. http://dx.doi.org/10.15407/biotech10.03.041.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Triplett, Douglas A. "Antiphospholipid Antibodies." Archives of Pathology & Laboratory Medicine 126, no. 11 (November 1, 2002): 1424–29. http://dx.doi.org/10.5858/2002-126-1424-aa.

Full text

Abstract:

Abstract Objective.—To review the role of lupus anticoagulants in the pathogenesis of both venous and arterial thromboembolic events, as well as in recurrent spontaneous abortions. The pathophysiology of lupus anticoagulants and associated antiphospholipid antibodies (eg, anticardiolipin antibodies) is also discussed. Data Sources.—Review of the recent medical literature. Data Extraction and Synthesis.—Key articles in the recent medical literature dealing with lupus anticoagulants and their role in pathogenesis of thromboembolic events were reviewed. Plasma proteins that have an affinity for binding to “perturbed cellular membranes” have been identified as the antigenic targets for antiphospholipid antibodies. Thus, the concept of antiphospholipid antibodies needs to be reevaluated. Perhaps a better term is antiprotein-phospholipid antibodies. The principal antigenic protein targets are β2-glycoprotein I, prothrombin, and a wide range of additional proteins that interact with activated cellular membranes, including protein C, protein S, annexin V, etc. Most research reported in the literature has focused on β2-glycoprotein I and human prothrombin.

APA, Harvard, Vancouver, ISO, and other styles

23

Brinkmann, Ulrich, and Roland E. Kontermann. "Bispecific antibodies." Science 372, no. 6545 (May 27, 2021): 916–17. http://dx.doi.org/10.1126/science.abg1209.

Full text

APA, Harvard, Vancouver, ISO, and other styles

24

Rieger, Paula Trahan. "Monoclonal Antibodies." American Journal of Nursing 87, no. 4 (April 1987): 469. http://dx.doi.org/10.2307/3470440.

Full text

APA, Harvard, Vancouver, ISO, and other styles

25

Groner, Bernd, Cord Hartmann, and Winfried Wels. "Therapeutic Antibodies." Current Molecular Medicine 4, no. 5 (August 1, 2004): 539–47. http://dx.doi.org/10.2174/1566524043360483.

Full text

APA, Harvard, Vancouver, ISO, and other styles

26

Kosmas, C., H. Kalofonos, and A. A. Epenetos. "Monoclonal Antibodies." Drugs 38, no. 5 (November 1989): 645–57. http://dx.doi.org/10.2165/00003495-198938050-00001.

Full text

APA, Harvard, Vancouver, ISO, and other styles

27

Larrick, James W., and Kirk E. Fry. "Recombinant antibodies." Human Antibodies 2, no. 4 (December 1, 1991): 172–89. http://dx.doi.org/10.3233/hab-1991-2401.

Full text

APA, Harvard, Vancouver, ISO, and other styles

28

Bronson, Richard A. "Sperm Antibodies." Immunology and Allergy Clinics of North America 10, no. 1 (February 1990): 165–84. http://dx.doi.org/10.1016/s0889-8561(22)00256-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

29

Pisetsky, David S. "ANTINUCLEAR ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 2 (May 1994): 371–85. http://dx.doi.org/10.1016/s0889-8561(22)00780-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Smith, J. Bruce, and F. Susan Cowchock. "ANTIPHOSPHOLIPID ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 4 (November 1994): 821–34. http://dx.doi.org/10.1016/s0889-8561(22)00345-9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

31

Pratt, Donna E. "THYROID ANTIBODIES." Immunology and Allergy Clinics of North America 14, no. 4 (November 1994): 835–38. http://dx.doi.org/10.1016/s0889-8561(22)00346-0.

Full text

APA, Harvard, Vancouver, ISO, and other styles

32

Visan, Ioana. "Enhancing antibodies." Nature Immunology 22, no. 7 (June 28, 2021): 800. http://dx.doi.org/10.1038/s41590-021-00973-7.

Full text

APA, Harvard, Vancouver, ISO, and other styles

33

Khamashta, Munther A., and Graham R. V. Hughes. "Antiphospholipid antibodies." Clinical Reviews in Allergy 12, no. 3 (September 1994): 287–96. http://dx.doi.org/10.1007/bf02802323.

Full text

APA, Harvard, Vancouver, ISO, and other styles

34

Adair, J., and A. Lawson. "Therapeutic Antibodies." Drug Design Reviews - Online 2, no. 3 (May 1, 2005): 209–17. http://dx.doi.org/10.2174/1567269053828800.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Pullen, Richard L. "Antinuclear antibodies." Nursing Made Incredibly Easy! 20, no. 6 (November 2022): 47–48. http://dx.doi.org/10.1097/01.nme.0000884112.83689.31.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Santos-Argumedo, Leopoldo. "Natural Antibodies." Advances in Neuroimmune Biology 3, no. 3,4 (2012): 345–52. http://dx.doi.org/10.3233/nib-012912.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

&NA;. "Monoclonal antibodies." Reactions Weekly &NA;, no. 1293 (March 2010): 36. http://dx.doi.org/10.2165/00128415-201012930-00100.

Full text

APA, Harvard, Vancouver, ISO, and other styles

38

Hudson, Peter J., and Christelle Souriau. "Engineered antibodies." Nature Medicine 9, no. 1 (January 2003): 129–34. http://dx.doi.org/10.1038/nm0103-129.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Benkovic, Stephen J. "Catalytic Antibodies." Annual Review of Biochemistry 61, no. 1 (June 1992): 29–54. http://dx.doi.org/10.1146/annurev.bi.61.070192.000333.

Full text

APA, Harvard, Vancouver, ISO, and other styles

40

Harris, E. Nigel. "ANTIPHOSPHOLIPID ANTIBODIES." British Journal of Haematology 74, no. 1 (July 7, 2008): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1988.00491.x-i1.

Full text

APA, Harvard, Vancouver, ISO, and other styles

41

Harris, E. Nigel. "ANTIPHOSPHOLIPID ANTIBODIES." British Journal of Haematology 74, no. 1 (January 1990): 1–9. http://dx.doi.org/10.1111/j.1365-2141.1990.tb02530.x.

Full text

APA, Harvard, Vancouver, ISO, and other styles

42

Drlicek, M., U. Liszka, W. Grisold, A. Mohn-Staudner, F. Lintner, and K. Jellinger. "Antineuronal antibodies." Neurology 40, no. 11 (November 1, 1990): 1804. http://dx.doi.org/10.1212/wnl.40.11.1804-b.

Full text

APA, Harvard, Vancouver, ISO, and other styles

43

Helmerhorst, F. M., M. J. J. Finken, and J. J. Erwich. "Antisperm antibodies." Human Reproduction 14, no. 7 (July 1999): 1669–71. http://dx.doi.org/10.1093/humrep/14.7.1669.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Worland, PhD, Peter J., Gary S. Gray, PhD, Mark Rolfe, PhD, Karen Gray, PhD, and Jeffrey S. Ross, MD. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (April 1, 2003): 472–85. http://dx.doi.org/10.1309/y6lp-c0lr-726l-9dx9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Ross, Jeffrey S., Karen Gray, Gary S. Gray, Peter J. Worland, and Mark Rolfe. "Anticancer Antibodies." American Journal of Clinical Pathology 119, no. 4 (April 2003): 472–85. http://dx.doi.org/10.1309/y6lpc0lr726l9dx9.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Barahona-Garrido, J., J. Camcho-Escobedo, C. Garcia-Martiʼnez, H. Tocay, J. Cabiedes, and J. Yamamoto-Furusho. "Antinuclear antibodies." Inflammatory Bowel Diseases 14 (December 2008): S12. http://dx.doi.org/10.1097/00054725-200812001-00038.

Full text

APA, Harvard, Vancouver, ISO, and other styles

47

Persidis, Aris. "Catalytic antibodies." Nature Biotechnology 15, no. 12 (November 1997): 1313–15. http://dx.doi.org/10.1038/nbt1197-1313.

Full text

APA, Harvard, Vancouver, ISO, and other styles

48

Tramontano, A., K. Janda, and R. Lerner. "Catalytic antibodies." Science 234, no. 4783 (December 19, 1986): 1566–70. http://dx.doi.org/10.1126/science.3787261.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

&NA;. "Monoclonal Antibodies." Journal of Pediatric Hematology/Oncology 25, no. 4 (April 2003): S5—S6. http://dx.doi.org/10.1097/00043426-200304000-00025.

Full text

APA, Harvard, Vancouver, ISO, and other styles

50

&NA;. "Monoclonal Antibodies." Journal of Pediatric Hematology/Oncology 25, no. 4 (April 2003): S17—S18. http://dx.doi.org/10.1097/00043426-200304000-00036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!